Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) 是重组的人源化单克隆抗体，靶向 IGF 配体IGF1和IGF2。Xentuzumab 抑制IGF1和IGF2的生长促进信号，抑制AKT的激活。
| 生物活性 | Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a humanized monoclonal antibody that targets IGF ligandsIGF1andIGF2. Xentuzumab inhibits both ofIGF1andIGF2growth-promoting signalling and suppressesAKTactivation[1]. |
| IC50& Target | |
体外研究
(In Vitro) | Xentuzumab (0.01-1 mM; 96 h) inhibits IGF type 1 receptor signaling and (0.1 μM; 48 h) AKT serine/threonine kinase (AKT) phosphorylation in VCaP, DuCaP, and MDA PCa 2b cell in a dose-dependent manner[1].
Xentuzumab (0.01-1 mM; 5-10 d) losses of antiproliferative activity against PTEN-null LNCaP or PC-3 cells when PTEN knockdown[1].
Xentuzumab (1 μM; 24-72 h) arrests cell cycle at sub-G1 phase and induces apoptosis in VCaP cells[1].
Western Blot Analysis[1] | Cell Line: | Prostate cancer VCaP cells | | Concentration: | 0.1 μM | | Incubation Time: | 24 h and 48 h | | Result: | Increased in cleaved caspase 3/7 and PARP.
Decreased the level of phosphorylation of FoxO3a (S253)/FoxO1 (T24). |
Cell Cycle Analysis[1] | Cell Line: | Prostate cancer VCaP cells | | Concentration: | 1 μM | | Incubation Time: | 24 h, 48 h, and 72 h | | Result: | Increased in cleaved caspase 3/7 and induces cell apoptosis.
Increased the sub-G1 cell population. |
|
体内研究
(In Vivo) | Xentuzumab (200 mg/kg i.p., once weekly for 10 weeks) in inhibits tumor growth in LuCaP 96CR patient-derived xenograft model in mice[1].
| Animal Model: | Fox Chase CB17 severe combined immunodeficiency (SCID; CB17/lcr-Prkdc scid/lcrlcoCrl) male mice with LuCaP 96CR cell (s.c.)[1] | | Dosage: | 200 mg/kg | | Administration: | Intraperitoneal injection; once weekly for 10 weeks; sacrificed 6 hours after the last dose | | Result: | Resulted in significant reductions in tumor volume. |
|
| CAS 号 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com